Bispecific/Multispecific Ab Discovery Platforms

WuXiBody TM Advantages

Fast development and no CMC challenges

Development/CMC Advantages

Engineering Advantages

• Saves 6-18 months of development time • Reduces manufacturing costs by as much as 90% • Can be used in both fed-batch and concentrated fed-batch production • Provides high protein expression in CHO cells (2-5 g/L, >30 g/L intensified perfusion culture (IPC)) • No aggregation issues • Very stable: >2 weeks in serum at 37 °C • High solubility: 30-100 mg/ml • Similar yield to mAbs

• Compatible with almost any mAb sequence • Available in both symmetric and asymmetrical formats

• Accommodates different valency formats (bi, tri and tetra) based on project needs and biology • Provides similar purification schemes as for mAbs • Ensures long In vivo half-life • Utilizes natural human sequence without complicated engineering resulting in low immunogenicity

SDArBody TM MsAb Technology Platform

SDArBody is a novel technology platform to enable the generation of multispecific proteins utilizing WuXi Biologics’ unique VHH libraries and discovery capabilities. This highly flexible platform offers our clients the ability to generate multispecific antibodies with high affinity, low immunogenicity risk and excellent developability characteristics.

Multiple Approaches to Discover VHH Leads

VHH Optimization

SDArBody Engineering

• >10 11 size naïve library from 100+ alpaca donors • >10 11 size humanized synthetic VHH library • Immune library based on proprietary immunization protocol to achieve desired immune responses Phage display • Cutting edge Berkeley Lights Beacon system • Proprietary antibody to isolate alpaca plasma cells Single B cell selection

Humanization

VHH Advantages: • High Affinities • Smaller molecular size • Ideal for binding to difficult targets and epitopes • Excellent developability • Low immunogenicity risk • Great flexibility in building multispecific biologic

Ainity Maturation

1-4 months

2-3 months

1-2 months

Multiple VHH lead generation and screening approaches have been developed for the SDArBody platform, including traditional phage display, and single B cell selection. After humanization (and optional affinity maturation), the VHH leads can be freely assembled into SDArBody msAb.